High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome

Leukemia Research

Volumn 38, Issue 8, 2014, Pages 874-881

  Calvo, Xavier ^a   Nomdedeu, Meritxell ^a,b   Navarro, Alfons ^a   Tejero, Rut ^a   Costa, Dolors ^a   Muñoz, Concha ^a   Pereira, Arturo ^a   Peña, Oscar ^a   Risueño, Ruth M ^b   Monzó, Mariano ^a   Esteve, Jordi ^a,b   Nomdedeu, Benet ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE IJC   (Spain)

Author keywords

5 hmC; 5 mC; Hydroxymethylation; Methylation; Myelodysplastic syndromes; Prognosis

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; HEMOGLOBIN;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA HYDROXYMETHYLATION; DNA METHYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKEMIA; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; METHYLATION; MYELODYSPLASTIC SYNDROME; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM; WHO CLASSIFICATION BASED PROGNOSTIC SCORING SYSTEM;

5-HMC; 5-MC; HYDROXYMETHYLATION; METHYLATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

5-METHYLCYTOSINE; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CYTOSINE; DNA; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84904543823     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.04.015     Document Type: Article

References (46)

1. Tefferi A., Vardiman J.W. Mechanisms of disease - myelodysplastic syndromes. N Engl J Med 2009, 361:1872-1885.
2. Schanz J., Steidl C., Fonatsch C., Pfeilstöcker M., Nösslinger T., Tuechler H., et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011, 29(15):1963-1970.
3. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89(6):2079-2088.
4. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25(23):3503-3510.
5. Kantarjian H., O'Brien S., Ravandi F., Cortes J., Shan J., Bennett J.M., et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008, 113(6):1351-1361.
6. Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Solé F., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120(12):2454-2465.
7. Cordoba I., Gonzalez-Porras J.R., Such E., Nomdedeu B., Luño E., de Paz R., et al. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. Leuk Res 2012, 36(3):287-292.
8. Gonzalez-Porras J.R., Cordoba I., Such E., Nomdedeu B., Vallespi T., Carbonell F., et al. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer 2011, 117(24):5529-5537.
9. Della Porta M.G., Malcovati L., Boveri E., Travaglino E., Pietra D., Pascutto C., et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 2009, 27(5):754-762.
10. Guías españolas de diagnóstico y tratamiento de los síndromes mielodisplásicos y la leucemia mielomonocítica crónica Grupo Español de Síndromes Mielodisplásicos (GESMD), Sociedad Española de Hematología y Hemoterapia (SEHH). Haematologica/edición española 2012, 97(Suppl. 5):11-14.
11. Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364(26):2496-2506.
12. Papaemmanuil E., Cazzola M., Boultwood J., Malcovati L., Vyas P., Bowen D., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011, 365(15):1384-1395.
13. Malcovati L., Papaemmanuil E., Bowen D.T., Boultwood J., Della Porta M.G., Pascutto C., et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011, 118(24):6239-6246.
14. Graubert T., Walter M.J. Genetics of myelodysplastic syndromes: new insights. Hematol Am Soc Hematol Educ Program 2011, 2011:543-549.
15. Graubert T.A., Shen D., Ding L., Okeyo-Owuor T., Lunn C.L., Shao J., et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012, 44(1):53-57.
16. Walter M.J., Ding L., Shen D., Shao J., Grillot M., McLellan M., et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011, 25(7):1153-1158.
17. Makishima H., Visconte V., Sakaguchi H., Jankowska A.M., Abu Kar S., Jerez A., et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012, 119(14):3203-3210.
18. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349(21):2042-2054.
19. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6):415-428.
20. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324(5929):930-935.
21. Ito S., D'Alessio A.C., Taranova O.V., Hong K., Sowers L.C., Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466(7310):1129-1133.
22. Zhang H., Zhang X., Clark E., Mulcahey M., Huang S., Shi Y.G. TET1 is a DNA-binding protein that modulates DNA methylation and gene transcription via hydroxylation of 5-methylcytosine. Cell Res 2010, 20(12):1390-1393.
23. Guo J.U., Su Y., Zhong C., Ming G.L., Song H. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle Georget Tex 2011, 10(16):2662-2668.
24. Lin J., Yao D., Qian J., Wang Y.L., Han L.X., Jiang Y.W., et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leuk Res 2008, 32(10):1541-1545.
25. Quesnel B., Guillerm G., Vereecque R., Wattel E., Preudhomme C., Bauters F., et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998, 91(8):2985-2990.
26. Tien H.F., Tang J.H., Tsay W., Liu M.C., Lee F.Y., Wang C.H., et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 2001, 112(1):148-154.
27. Wu S.J., Yao M., Chou W.C., Tang J.L., Chen C.Y., Ko B.S., et al. Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br J Haematol 2006, 135(3):317-323.
28. Aggerholm A., Holm M.S., Guldberg P., Olesen L.H., Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006, 76(1):23-32.
29. Shen L., Kantarjian H., Guo Y., Lin E., Shan J., Huang X., et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010, 28(4):605-613.
30. Poloni A., Goteri G., Zizzi A., Serrani F., Trappolini S., Costantini B., et al. Prognostic role of immunohistochemical analysis of 5 mc in myelodysplastic syndromes. Eur J Haematol 2013, 91(3):219-227.
31. Liu X., Guangsen Z., Yi Y., Xiao L., Pei M., Liu S., et al. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes. Leuk Lymphom. 2013, [Epub ahead of print, March 27, 2013].
32. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10(3):223-232.
33. R: a language and environment for statistical computing 2008, Computing RFfS, Vienna Austria, http://www.R-project.org.
34. Grønbæk K., Müller-Tidow C., Perini G., Lehmann S., Bach Treppendahl M., Mills K., et al. A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies. Haematologica 2012, 97(9):1380-1388.
35. Yang A.S., Estécio M.R., Doshi K., Kondo Y., Tajara E.H., Issa J.P. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucl Acids Res 2004, 32(3):e38.
36. Huang Y., Pastor W.A., Shen Y., Tahiliani M., Liu D.R., Rao A. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS ONE 2010, 5(1):e8888.
37. Follo M.Y., Russo D., Finelli C., Mongiorgi S., Clissa C., Filì C., et al. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. Leukemia 2012, 26(5):943-950.
38. Valinluck V., Sowers L.C. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res 2007, 67(3):946-950.
39. Reitman Z.J., Jin G., Karoly E.D., Spasojevic I., Yang J., Kinzler K.W., et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A 2011, 108(8):3270-3275.
40. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19(1):17-30.
41. Kosmider O., Gelsi-Boyer V., Cheok M., Grabar S., Della-Valle V., Picard F., et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009, 114(15):3285-3291.
42. Smith A.E., Mohamedali A.M., Kulasekararaj A., Lim Z., Gäken J., Lea N.C., et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010, 116(19):3923-3932.
43. Delhommeau F., Dupont S., Della Valle V., James C., Trannoy S., Massé A., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360(22):2289-2301.
44. Langemeijer S.M., Kuiper R.P., Berends M., Knops R., Aslanyan M.G., Massop M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41(7):838-842.
45. Ko M., Huang Y., Jankowska A.M., Pape U.J., Tahiliani M., Bandukwala H.S., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468(7325):839-843.
46. Lian C.G., Xu Y., Ceol C., Wu F., Larson A., Dresser K., et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012, 150(6):1135-1146.